UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 114,647 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 13.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 939,170 shares of the company's stock after acquiring an additional 114,647 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.78% of Privia Health Group worth $18,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. First Horizon Advisors Inc. increased its holdings in Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after acquiring an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Privia Health Group by 7,833.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock valued at $47,000 after acquiring an additional 2,350 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock valued at $95,000 after acquiring an additional 511 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Privia Health Group by 185.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock valued at $98,000 after acquiring an additional 3,249 shares during the last quarter. Finally, KBC Group NV increased its holdings in Privia Health Group by 48.1% in the 4th quarter. KBC Group NV now owns 5,012 shares of the company's stock valued at $98,000 after acquiring an additional 1,627 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Privia Health Group

In other news, CFO David Mountcastle sold 5,630 shares of the business's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total value of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares in the company, valued at approximately $4,021,148.88. The trade was a 3.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Parth Mehrotra sold 15,100 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $352,283.00. Following the completion of the sale, the chief executive officer now owns 454,281 shares of the company's stock, valued at approximately $10,598,375.73. This represents a 3.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,579 shares of company stock valued at $1,226,367 in the last three months. Company insiders own 10.70% of the company's stock.

Privia Health Group Trading Up 1.4%

Shares of PRVA stock traded up $0.31 during trading hours on Friday, reaching $22.86. 1,260,625 shares of the stock were exchanged, compared to its average volume of 739,124. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 228.62, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. Privia Health Group, Inc. has a 12-month low of $16.37 and a 12-month high of $26.09. The company's 50-day moving average price is $23.34 and its 200-day moving average price is $22.72.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PRVA. Barclays boosted their target price on shares of Privia Health Group from $23.00 to $24.00 and gave the stock an "equal weight" rating in a report on Tuesday. JMP Securities restated a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a report on Monday, April 28th. JPMorgan Chase & Co. boosted their target price on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday. Robert W. Baird boosted their target price on shares of Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, April 15th. Finally, Piper Sandler boosted their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $27.77.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.